Lawrence Zumo
Silver Springs, MDNPI 1093882680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novartis at 26.8% of the total.
Across 162 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$795
- Biogen$606
- AbbVie$312
- Lilly USA, LLC$188
- Sanofi$132
- Sumitomo Pharma America, Inc.$115
- plus $816 from 18 others
What the payments were for
- Food & beverage$2,964100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 48 | $795 |
| Biogen | 32 | $606 |
| AbbVie(2 entities) | 18 | $312 |
| Lilly USA, LLC | 9 | $188 |
| Sanofi | 7 | $132 |
| Sumitomo Pharma America, Inc. | 8 | $115 |
| UCB, Inc. | 5 | $108 |
| Argenx US, Inc. | 4 | $90 |
| Biohaven Pharmaceuticals, Inc. | 5 | $87 |
| AstraZeneca | 4 | $85 |
| Novo Nordisk | 4 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Global Blood Therapeutics, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| SK Life Science, Inc. | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $18 |
| Livanova USA, Inc. | 1 | $17 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 31 | $716 |
| Donepezil Hcl | 15 | $273 |
| ClopidogrelClopidogrel Bisulfate | 12 | $101 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.